Telmisartan 80 mg (Film-coated tablet)

1. Description: Clinical summary

Telmisartan 80 mg is an oral antihypertensive medication in the angiotensin II receptor blocker (ARB) class. The active compound, telmisartan, is used primarily to treat hypertension and to reduce cardiovascular morbidity in selected high‑risk patients. It produces sustained blood‑pressure lowering with once‑daily dosing due to a long half‑life. Compared with ACE inhibitors, ARBs (including telmisartan) are less likely to cause cough and are an alternative when ACE inhibitors are not tolerated. Telmisartan is contraindicated during pregnancy because of the risk of fetal injury and death.

Typical therapeutic uses

• Essential (primary) hypertension (monotherapy or in combination with other antihypertensives, e.g., diuretics).
• Reduction of cardiovascular morbidity in patients (often older/high‑risk) as indicated by clinical trials (specific indications vary by country and product labeling).
• Off‑label or investigational uses include some renal and vascular protection contexts; established use for diabetic nephropathy is less robust than for certain other ARBs.

Key pharmacologic properties

• Highly selective antagonist of angiotensin II type 1 (AT1) receptors.
• Long elimination half‑life permits once‑daily dosing.
• Highly protein bound; primarily eliminated via biliary excretion.

2. How does Telmisartan 80mg work? (Mechanism of action)

• Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor.
• By preventing angiotensin II binding at AT1 receptors, telmisartan inhibits vasoconstriction, aldosterone secretion, sympathetic activation, cellular growth and proliferation mediated by angiotensin II.
• The result is arterial vasodilation, reduced peripheral vascular resistance, decreased salt and water retention (via lower aldosterone), and thereby a reduction in blood pressure.
• Because it does not inhibit bradykinin breakdown (unlike ACE inhibitors), telmisartan generally causes less cough and lower risk of bradykinin‑related angioedema, though angioedema can still occur rarely.

3. Dosage: Medical and varying usage guidelines

General adult dosing (typical; adjust per product label and patient factors)

• Usual starting dose for most adults: 20–40 mg once daily.
• Common maintenance dose: 40 mg once daily.
• Maximum recommended dose: 80 mg once daily (Telmisartan 80 mg is the maximum usual single‑dose marketed strength).
• For many indications (e.g., high cardiovascular risk), 80 mg once daily is the dose used for maximal effect.

Specific situations and precautions

• Elderly: No routine dose adjustment required; start cautiously if volume depleted or with concurrent diuretics.
• Volume‑depleted or sodium‑depleted patients (e.g., on high‑dose diuretics): correct volume depletion before starting or begin with lower dose and monitor for symptomatic hypotension.
• Renal impairment: No fixed dose reduction is generally required, but monitor renal function and potassium closely after initiation or dose changes. In patients with bilateral renal artery stenosis, ARBs may cause azotemia—use with caution.
• Hepatic impairment: Telmisartan is eliminated mainly via the biliary route and exposure may be increased in hepatic impairment. Exercise caution and consider lower starting doses; in severe hepatic impairment, telmisartan may be not recommended—follow local product labeling.
• Pediatrics: Limited and variable data across regions. Use only if recommended by pediatric specialist and follow approved pediatric dosing where available.

Administration tips

• Once‑daily dosing, with or without food. Taking at the same time each day improves adherence.
• If a dose is missed, take it as soon as remembered unless it is near the time of the next dose—do not double doses.

Monitoring after initiation or dose change

• Blood pressure (for response and hypotension).
• Serum creatinine and blood urea nitrogen (BUN) to detect renal function changes.
• Serum potassium (risk of hyperkalemia).
• Consider more frequent monitoring during the first 1–2 weeks after starting or increasing dose, and whenever combinations that affect renal function/potassium are started.

Drug combinations and cautions

• Combining with ACE inhibitors or aliskiren: increased risk of hypotension, hyperkalemia, and renal impairment; avoid combinations in many patients, particularly those with diabetes or renal dysfunction.
• Combination with thiazide diuretics or amlodipine is commonly used when monotherapy is insufficient.

Always follow local prescribing information and individualized clinical judgment.

4. Side effects: Common and rare adverse effects

Common (more likely)

• Dizziness, especially on standing or after the first doses (orthostatic hypotension).
• Fatigue, weakness.
• Upper respiratory infection symptoms, nasopharyngitis.
• Diarrhea, abdominal pain.
• Back pain.

Less common / important laboratory abnormalities

• Elevated serum potassium (hyperkalemia).
• Increased serum creatinine or reduced renal function (usually reversible if recognized early).

Rare but serious

• Angioedema (rare; can occur with ARBs—life‑threatening airway compromise in extreme cases).
• Acute renal failure, particularly in patients with bilateral renal artery stenosis or on concomitant diuretics/NSAIDs.
• Severe hypotension (syncope) after first dose or in volume‑depleted patients.
• Cholestatic hepatitis or clinically significant hepatic dysfunction (very rare).
• Hypersensitivity reactions.

Drug interaction related adverse risks

• NSAIDs (including selective COX‑2 inhibitors): may reduce antihypertensive effect and increase risk of renal impairment.
• Potassium‑sparing diuretics, potassium supplements, and potassium‑containing salt substitutes: raise risk of hyperkalemia.
• Lithium: risk of increased lithium levels and lithium toxicity — monitor closely if coadministered.

Pregnancy and lactation

• Contraindicated in pregnancy (second and third trimester) — risk of fetal renal dysplasia, oligohydramnios, skull hypoplasia and fetal/neonatal death. Discontinue as soon as pregnancy is detected.
• Use during breastfeeding: limited data; avoid or discuss alternatives with clinician.

If severe adverse effects occur (e.g., angioedema, anuria, severe hypotension), seek urgent medical care.

5. Storage: HOW to store it

• Store at controlled room temperature: commonly recommended 20–25°C (68–77°F). Short permitted excursions (e.g., 15–30°C/59–86°F) may be acceptable depending on regional labeling—follow the specific product package insert.
• Protect from excessive moisture and heat. Keep tablets in original blister pack or container until use to maintain stability and to protect from light and humidity.
• Keep out of reach and sight of children.
• Do not use after the expiry date printed on the packaging.
• Dispose of unused or expired medicine in accordance with local regulations—do not flush medications down the toilet unless instructed.

Additional practical advice (patient counseling points)

• Take once daily at the same time; may be taken with or without food.
• Avoid starting aspirin/NSAIDs chronically without checking with a clinician.
• Inform clinicians about all other medicines including potassium supplements, herbal products (e.g., St. John’s wort), and over‑the‑counter agents.
• If pregnancy is planned or suspected, stop telmisartan immediately and contact a healthcare provider.

Note: This guide is educational and intended to summarize commonly accepted clinical information. Always follow the specific product label, local clinical guidelines, and the prescribing clinician’s instructions for individual patients.